✦ LIBER ✦

Potential biomarkers of long-term benefit from single-agent trastuzumab or lapatinib in HER2-positive metastatic breast cancer

✍ Scribed by Montemurro, Filippo; Prat, Aleix; Rossi, Valentina; Valabrega, Giorgio; Sperinde, Jeff; Peraldo-Neia, Caterina; Donadio, Michela; Galván, Patricia; Sapino, Anna; Aglietta, Massimo; Baselga, José; Scaltriti, Maurizio

Book ID: 121295078
Publisher: Wiley (John Wiley & Sons)
Year: 2013
Tongue: English
Weight: 323 KB
Volume: 8
Category: Article
ISSN: 1574-7891
DOI: 10.1016/j.molonc.2013.08.013

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Lapatinib or trastuzumab in combination

Lapatinib or trastuzumab in combination with an aromatase inhibitor for first-line treatment of metastatic hormone-receptor-positive breast cancer that overexpresses HER2

✍ Sally Doss; Janet Robertson; Jane Adam 📂 Article 📅 2012 🏛 The Lancet 🌐 English ⚖ 42 KB

Benefit of continuing trastuzumab beyond

Benefit of continuing trastuzumab beyond progression in her2-positive metastatic breast cancer (mbc) is independent of the chemotherapy partner: message from a single-centre retrospective study

✍ Raffaella Palumbo; Federico Sottotetti; Antonio Bernardo; Maria Rosa Strada; Alb 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 60 KB

490 Long term survival and incidence of

490 Long term survival and incidence of brain metastasis in HER2- positive (HER2+) metastatic breast cancer patients (MBC) treated with trastuzumab (T): an institutional based review

✍ V. Diéras; M.N. Guilhaume; M. Fall; J.Y. Pierga; P. Beuzeboc; P. Cottu; C. Simon 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 66 KB

Overall Survival Benefit With Lapatinib

Overall Survival Benefit With Lapatinib in Combination With Trastuzumab for Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer: Final Results From the EGF104900 Study

✍ Blackwell, K. L.; Burstein, H. J.; Storniolo, A. M.; Rugo, H. S.; Sledge, G.; Ak 📂 Article 📅 2012 🏛 American Society of Clinical Oncology 🌐 English ⚖ 203 KB

Efficacy, safety, pharmacokinetics and b

Efficacy, safety, pharmacokinetics and biomarker findings in patients with HER2-positive advanced or metastatic breast cancer treated with lapatinib in combination with capecitabine: results from 51 Japanese patients treated in a clinical study

✍ Iwata, Hiroji; Fujii, Hirofumi; Masuda, Norikazu; Mukai, Hirofumi; Nishimura, Yu 📂 Article 📅 2013 🏛 Springer Japan 🌐 English ⚖ 300 KB

Final results of a multicenter phase II

Final results of a multicenter phase II clinical trial evaluating the activity of single-agent lapatinib in patients with HER2-negative metastatic breast cancer and HER2-positive circulating tumor cells. A proof-of-concept study

✍ Marta Pestrin, Silvia Bessi, Fabio Puglisi, Alessandro M. Minisini, Giovanna Mas 📂 Article 📅 2012 🏛 Springer US 🌐 English ⚖ 246 KB